Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT combined with KarX-EC in adults aged 55 to 90 who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study aims to better understand how these treatments may impact agitation symptoms in this population. The study is sponsored by Bristol-Myers Squibb and focuses on agitation as a complication of Alzheimers disease. Participants will be randomly assigned to receive either the combination of XanomelineTrospium Chloride Capsule and Xanomeline Enteric Capsule or a placebo. The treatments are given at specified doses on designated days. The study uses a parallel group design to compare these two options over a treatment period lasting up to 14 weeks. During the study, participants and their caregivers will attend regular visits for assessments including agitation severity using the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association total score, clinical global impressions, and other neuropsychiatric evaluations. Safety will be closely monitored through adverse event reporting and various clinical tests, including movement scales, vital signs, lab tests, ECGs, and assessments for suicidal thoughts. Caregivers will help oversee medication compliance and report on participant status. The entire study period extends through Week 18 for safety follow-up.
Actively Recruiting
Researchers are studying how well Immune Globulin Infusion IGI, 10% can help prevent infections in adults with multiple myeloma who are receiving a special bispecific antibody therapy targeting B-cell maturation antigen BCMA and CD3. The trial compares two groups one receiving IGI, 10% regularly for 12 months as primary infection prevention, and the other receiving IGI, 10% only if they develop a serious infection during the study period. This is a Phase 3, randomized, open-label study sponsored by Takeda. Participants will be randomly assigned to either receive IGI, 10% intravenously every 3 or 4 weeks for 12 months regardless of infections or receive it only after experiencing at least one serious infection during the 12-month observation. The dosing is based on standard care, with a dose of 400 mgkg given within 3 days after randomization. The study design includes 15 to 19 clinic visits depending on dosing intervals. During the study, participants will be monitored for serious infections and other infection-related outcomes up to 12 months. Researchers will measure the time to first serious infection as the primary outcome, along with rates of infections, antibiotic use, hospitalizations, and immune response markers such as immunoglobulin G levels. Safety will also be assessed by tracking adverse events related to IGI, 10%. Total participation lasts up to 14 months including an approximately 8-week screening period.
Actively Recruiting
Researchers are investigating the long-term safety and effectiveness of a combined drug treatment using xanomeline tartratetrospium chloride in an immediate release capsule KarXT and xanomeline enteric capsules KarX-EC for people with agitation linked to Alzheimers Disease. This study is an open-label extension of earlier studies CN012-0023 and CN012-0024. It aims to understand how well these treatments work over time and monitor any side effects. Participants who completed the previous studies will receive specified doses of KarXT and KarX-EC according to a set schedule. This phase 3 study does not include a comparison group and all participants receive the combined treatment. The treatment period lasts approximately 30 weeks, during which the effects and safety of these medications will be observed. During the study, participants will be closely monitored for any adverse events, changes in cognitive function, movement disorders, vital signs, and other health measures. Assessments include scales like the Mini-Mental State Examination MMSE, Abnormal Involuntary Movement Scale AIMS, and others related to agitation and side effects. Safety checks such as lab tests, ECGs, and questionnaires will be regularly conducted. The total study duration for participants is about 30 weeks, with follow-up to evaluate overall treatment tolerability and impact.
Actively Recruiting
This research aims to improve the accuracy of MRI scans in detecting early-stage rectal cancer and significant rectal polyps. Many patients with early rectal cancer currently undergo major surgery or unnecessary treatments due to inaccurate staging. The study evaluates a new MRI reading method called PRESERVE, which has been shown to identify early rectal cancers more accurately and may allow more patients to have less invasive local excision surgery that preserves the rectum and quality of life. The study compares two phases a control phase where patients receive standard care, and an intervention phase following training of radiologists in the PRESERVE MRI staging method. During the intervention phase, MRI scans are recommended for rectal polyps 20mm or larger or with suspicious features before removal, alongside radiologist training. Each hospital transitions from control to intervention at a randomized time, with no crossover of patients between phases. Participants will be monitored through clinical investigations before, during, and after treatment as per standard care. Researchers will assess the accuracy of tumor staging on MRI, the number of patients identified for rectal preservation surgery, and quality of life outcomes over up to 5 years. Additional measures include scan quality, tumor characteristics, treatment costs, and histopathological biomarkers. The primary outcome is the impact of radiologist training on staging accuracy measured after one year.
Actively Recruiting
Researchers are evaluating the impact of two different default dialysate sodium concentrations on major cardiovascular events and death in adults receiving maintenance haemodialysis for end-stage kidney disease. This pragmatic, cluster-randomised, open-label Phase 4 study compares sodium levels of 137 mmoll and 140 mmoll in real-world dialysis settings across multiple sites globally. Dialysis sites will be randomly assigned to use either a default dialysate sodium concentration of 137 mmoll or 140 mmoll for at least 90% of dialysis sessions. Other aspects of patient care will follow standard local practices. Sites must consent to participate, and individual patients will provide waiver or opt-out consent. The study expects to enroll sites over 5 to 7 years, with each participant followed for approximately 2 to 5 years until the study endpoints are reached. Participants will receive dialysis at their assigned sites with the designated sodium concentration. Researchers will monitor the time to first occurrence of major cardiovascular events or death as the primary outcome. Secondary outcomes include other cardiovascular events and individual components of the composite outcomes. Data collection and patient monitoring will continue throughout the study period, estimated to last around five years per participant.
Actively Recruiting
The trial investigates the role of ixazomib in patients with relapsed multiple myeloma who have previously undergone autologous stem cell transplant ASCT. It is a phase III, randomized, controlled, multi-center, open-label study aiming to assess whether adding a proteasome inhibitor to salvage ASCT conditioning improves depth of response and how consolidation and maintenance therapy influence the durability of response. The study also evaluates overall survival, progression-free survival, response rates, minimal residual disease, toxicity, and quality of life. Participants first receive re-induction therapy with 4 to 6 cycles of ixazomib, thalidomide, and dexamethasone ITD, each cycle lasting 28 days. Those achieving at least stable disease are randomly assigned to receive either conventional ASCT using melphalan alone or augmented ASCT combining melphalan with ixazomib. After ASCT, participants with minimal response or better are further randomized to either receive consolidation with 2 cycles of ITD followed by ixazomib maintenance until disease progression or no further treatment. During the study, participants undergo regular assessments including response evaluation 100 days post-ASCT, monitoring of progression-free survival for up to 120 months, and measurement of minimal residual disease at several time points. Safety and toxicity are closely monitored throughout re-induction, post-ASCT, consolidation, and maintenance phases. Quality of life questionnaires are completed at baseline, post-re-induction, post-ASCT, and during follow-up visits up to 24 months. The study plans to register 406 participants, with 284 randomized at the first stage and 248 at the second stage.